Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial
Mingyuan Zhang(Nanyang Technological University), Junqi Niu(Jilin University), Jia Shang(European Foundation for the Study of Chronic Liver Failure), Jinlin Hou(Southern Medical University), Qing Xie(Shanghai Jiao Tong University), Wenlian Xie(Fujian University of Traditional Chinese Medicine), Yulei Zhuang(HEC Pharm (China)), Jiajie Lu(Sichuan University), Robert G. Gish(California Pacific Medical Center), Jianqi Lian(Air Force Medical University), Peng Hu(The Ohio State University), Zhiliang Gao(Sun Yat-sen University), Huiying Rao(Peking University), Yanhang Gao(Jilin University), Zhenjing Jin(Second Affiliated Hospital of Jilin University), Sujun Zheng(Beijing Tian Tan Hospital), Haibing Gao(Fujian Medical University), Shide Lin(Guangzhou University of Chinese Medicine), Yongxiang Yi(Nanjing University of Chinese Medicine), Maorong Wang(Qingdao University of Science and Technology), Liang Chen(Zhejiang University of Technology), Dongliang Yang, Lin Luo(Shanghai Jiao Tong University), Yingjun Zhang(HEC Pharm (China)), Huanyu Gong(Central South University), Yongning Xin(Qingdao University), Chao Wu(Qingdao University), Fei Kong(Shanghai Jiao Tong University), Youwen Tan(Jiangsu University), Mao Mu(Guiyang Medical University), Xiaorong Mao(First Hospital of Lanzhou University), Tao Han(First Hospital of China Medical University), Yingren Zhao(First Affiliated Hospital of Xi'an Jiaotong University), Yunfu Chen(HEC Pharm (China))
Cited by 6
Related Papers
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336